Conference Coverage: EHA 2018
Paul G. Richardson, MD discusses EHA 2018 Abstract S847 – OPTIMISMM: Phase 3 Trial of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone vs Bortezomib and Low-Dose Dexamethasone in Lenalidomide-Exposed Patients with Relapsed/Refractory Multiple Myeloma
Dr. Francesca Gay discusses EHA 2018 abstract #PF560: Carfilzomib in Combination with Bendamustine and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Phase Ib/II Trial of the European Myeloma Network Trialist Group (EMNTG)
Dr. Karim Iskander discusses EHA 2018 abstract S849 – Once-Weekly vs Twice-Weekly Carfilzomib Dosing Plus Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results Of The Randomized Phase 3 Study A.R.R.O.W.
Dr. Bringhen discusses EHA 2018 abstract PS1293: Doublet vs Triplet Lenalidomide-Containing Regimens Followed by Maintenance: Subgroup Analysis by Frailty Status After a Median Follow-Up of 5 Years (EMN01 Phase III Study). The study challenges the “one-size-fits-all” approach to treating patients with multiple myeloma. This subset analysis of a large randomized phase III trial, demonstrated that that fit patients benefit from triplet full-dose regimens, while intermediate and frail patients benefit from a gentler doublet regimen.
Dr. Dinmohamed from the Netherlands Comprehensive Cancer Organisation (IKNL) discusses abstract PS1301 from the EHA meeting in Stockholm: Treatment and Survival of Patients with Primary Plasma Cell Leukemia: A Nationwide Population-Based Study Among 179 Patients Diagnosed in the Netherlands from 1989 to 2015
Dr. Gay discusses EHA 2018 Abstract S109: Updated Efficacy and MRD Data According To Risk-Status in Newly Diagnosed Myeloma Patients Treated with Carfilzomib Plus Lenalidomide or Cyclophosphamide: Results from the FORTE Trial